References
- Papers of special note have been highlighted as:
- • of interest
- •• of considerable interest
- Halstead SB, Jacobson J. Japanese encephalitis vaccines. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. 5th ed. Philadelphia (PA): Elsevier; 2008. Chapter 17.
- Pan XL, Liu H, Wang HY, et al. Emergence of genotype I of Japanese encephalitis virus as the dominant genotype in Asia. J Virol. 2011;85:9847–9853.
- Campbell GL, Hills SL, Fischer M, et al. Estimated global incidence of Japanese encephalitis: a systematic review. Bull World Health Organ. 2011;89:766–774.
- World Health Organization. Japanese encephalitis vaccines. Wkly Epidemiol Rec. 1998;73:337–344.
- World Health Organization. Japanese encephalitis vaccines: WHO position paper - February 2015. Wkly Epidemiol Rec. 2015;90:69–87.
- Lee DW, Choe YJ, Kim JH, et al. Epidemiology of Japanese encephalitis in South Korea, 2007–2010. Int J Infect Dis. 2012;16:e448–452.
- Hsu LC, Chen YJ, Hsu FK, et al. The incidence of Japanese encephalitis in Taiwan–a population-based study. PLoS Negl Trop Dis. 2014;8:e3030.
- Arai S, Matsunaga Y, Takasaki T, et al. Japanese encephalitis: surveillance and elimination effort in Japan from 1982 to 2004. Jpn J Infect Dis. 2008;61:333–338.
- Upreti SR, Janusz KB, Schluter WW, et al. Estimation of the impact of a Japanese encephalitis immunization program with live, attenuated SA 14-14-2 vaccine in Nepal. Am J Trop Med Hyg. 2013;88:464–468.
- Muangchana C, Henprasertthae N, Nurach K, et al. Effectiveness of mouse brain-derived inactivated Japanese encephalitis vaccine in Thai National Immunization Program: a case-control study. Vaccine. 2012;30:361–367.
- Hoke CH, Nisalak A, Sangawhipa N, et al. Protection against Japanese encephalitis by inactivated vaccines. N Engl J Med. 1988;319:608–614.
- Appaiahgari MB, Vrati S. IMOJEV((R)): a Yellow fever virus-based novel Japanese encephalitis vaccine. Expert Rev Vaccines. 2010;9:1371–1384.
- Chambers TJ, Nestorowicz A, Mason PW, et al. Yellow fever/Japanese encephalitis chimeric viruses: construction and biological properties. J Virol. 1999;73:3095–3101.
•• Describes the chimerization process used to produce JE-CV
- Guirakhoo F, Zhang ZX, Chambers TJ, et al. Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis. Virology. 1999;257:363–372.
•• Pre-clinical studies showed JE-CV is genetically stable and the chimeric vaccine is attenuated relative to the yellow fever virus
- Monath TP, Levenbook I, Soike K, et al. Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys. J Virol. 2000;74:1742–1751.
- Monath TP, Soike K, Levenbook I, et al. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates. Vaccine. 1999;17:1869–1882.
- Guy B, Guirakhoo F, Barban V, et al. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine. 2010;28:632–649.
•• An extensive and inclusive review that describes the development of YFV 17D-based chimeric vaccines
- Monath TP, Guirakhoo F, Nichols R, et al. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J Infect Dis. 2003;188:1213–1230.
- Monath TP, McCarthy K, Bedford P, et al. Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections. Vaccine. 2002;20:1004–1018.
- Reid M, Mackenzie D, Baron A, et al. Experimental infection of Culex annulirostris, Culex gelidus, and Aedes vigilax with a yellow fever/Japanese encephalitis virus vaccine chimera (ChimeriVax-JE). Am J Trop Med Hyg. 2006;75:659–663.
- Nasveld PE, Marjason J, Bennett S, et al. Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine: randomized double-blind phase II evaluation of safety and immunogenicity. Hum Vaccin. 2010;6:906–914.
- Nasveld PE, Ebringer A, Elmes N, et al. Long term immunity to live attenuated Japanese encephalitis chimeric virus vaccine: randomized, double-blind, 5-year phase II study in healthy adults. Hum Vaccin. 2010;6:1038–1046.
- Desai K, Coudeville L, Bailleux F. Modelling the long-term persistence of neutralizing antibody in adults after one dose of live attenuated Japanese encephalitis chimeric virus vaccine. Vaccine. 2012;30:2510–2515.
- Torresi J, McCarthy K, Feroldi E, et al. Immunogenicity, safety and tolerability in adults of a new single-dose, live-attenuated vaccine against Japanese encephalitis: randomised controlled phase 3 trials. Vaccine. 2010;28:7993–8000.
• Summarizes the immunogenicity and safety of JE-CV from two randomized studies undertaken in areas at low risk of JE (USA and Australia)
- Huang LM, Lin TY, Chiu CH, et al. Concomitant administration of live attenuated Japanese encephalitis chimeric virus vaccine (JE-CV) and measles, mumps, rubella (MMR) vaccine: randomized study in toddlers in Taiwan. Vaccine. 2014;32:5363–5369.
• First study to investigate co-administration of JE-CV with a second childhood vaccine (MMR)
- Chokephaibulkit K, Sirivichayakul C, Thisyakorn U, et al. Safety and immunogenicity of a single administration of live-attenuated Japanese encephalitis vaccine in previously primed 2- to 5-year-olds and naive 12- to 24-month-olds: multicenter randomized controlled trial. Pediatr Infect Dis J. 2010;29:1111–1117.
•• First trial to report safety and immunogenicity of JE-CV as a booster or a priming dose in children
- Feroldi E, Pancharoen C, Kosalaraksa P, et al. Single-dose, live-attenuated Japanese encephalitis vaccine in children aged 12-18 months: randomized, controlled phase 3 immunogenicity and safety trial. Hum Vaccin Immunother. 2012;8:929–937.
•• Large Phase III trial of JE-CV primary immunization in >1000 toddlers
- Feroldi E, Thisyakorn U, Pancharoen C, et al. Persistence of antibodies two years after a single injection of live attenuated Japanese encephalitis chimeric virus vaccine at 12-24 months of age. Presented at 7th World Congress of the World Society for Pediatric Infectious Diseases (WSPID); 2011 Nov 16–19; Melbourne, Australia
- Feroldi E, Kosalaraksa P, Watanaveeradej V, et al. Long-term neutralizing antibody response after a JE-CV single dose primary immunization in JE-vaccine naïve toddlers. Presented at the 5th Asian Vaccine Conference (ASVAC); 2015 Jun 12–14; Hanoi, Vietnam
- Feroldi E, Capeding MR, Boaz M, et al. Memory immune response and safety of a booster dose of Japanese encephalitis chimeric virus vaccine (JE-CV) in JE-CV-primed children. Hum Vaccin Immunother. 2013;9:889–897.
•• First trial in which children previously primed with JE-CV received a booster dose of JE-CV
- Chokephaibulkit K, Sabchareon A, Thisyakorn U, et al. Long-term neutralizing antibody response to a booster dose of a novel live-attenuated Japanese encephalitis vaccine (JE-CV - IMOJEV®) in a pediatric population. Presented at 7th Asian Congress of Pediatric Infectious Disease (ACPID); 2014 Oct 12–15; Beijing, China
- Kim DS, Jang GC, Cha SH, et al. Immunogenicity and safety of a booster dose of IMOJEV® 12 months after a primary vaccination in Korean children. Presented at the 7th Annual Meeting of ACPID; 2014 Oct 12–15; Beijing, China. 2014.
- Kosalaraksa P, Wiangnon S, Suphakunpinyo C, et al. Booster effect of Japanese encephalitis chimerix virus vaccine (JE-CV): 5 years after primary vaccination. Presented at the 5th Asian Vaccine Conference (ASVAC); 2015 Jun 12–14; Hanoi, Vietnam
- Feroldi E, Pancharoen C, Kosalaraksa P, et al. Primary immunization of infants and toddlers in Thailand with Japanese encephalitis chimeric virus vaccine in comparison with SA14-14-2: a randomized study of immunogenicity and safety. Pediatr Infect Dis J. 2014;33:643–649.
- Kim DS, Houillon G, Jang GC, et al. A randomized study of the immunogenicity and safety of Japanese encephalitis chimeric virus vaccine (JE-CV) in comparison with SA14-14-2 vaccine in children in the Republic of Korea. Hum Vaccin Immunother. 2014;10:2656–2663.
- Hombach J, Solomon T, Kurane I, et al. Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004. Vaccine. 2005;23:5205–5211.
•• Expert position paper addressing recommendations for specifications on immunological criteria to assess JE vaccine efficacy
- Bonaparte M, Dweik B, Feroldi E, et al. Immune response to live-attenuated Japanese encephalitis vaccine (JE-CV) neutralizes Japanese encephalitis virus isolates from south-east Asia and India. BMC Infect Dis. 2014;14:156.
• Study confirmed that JE-CV-induced antibodies that can also neutralize recent wt JE virus (JEV) isolates including a genotype 1 isolate in South East Asia and India
- Feroldi E, Bailleux F, Monfredo C, et al. Modeling the long-term persistence of neutralizing antibodies after booster vaccination with a novel live attenuated Japanese encephalitis vaccine (JE-CV) – modeling Ab persistence in children. Presented at 8th World Congress of the World Society for Pediatric Infectious Diseases (WSPID), 2013 Nov 19–22; Cape Town, South Africa